Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Phibro Animal Health Corporation (PAHC : NSDQ)
 
 • Company Description   
Phibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company. The company provides a broad range of products for food animals including poultry, swine, beef and dairy cattle and aquaculture. In addition to animal health and mineral nutrition products, Phibro manufactures and markets specific ingredients for use in the personal care, automotive, industrial chemical and chemical catalyst industries. Currently, Phibro focuses on regions where the majority of livestock production is consolidated in large commercial farms such as the U.S., Brazil, China, Russia, Mexico, Australia, Turkey, Israel, Canada and Europe.

Number of Employees: 1,860

 
 • Price / Volume Information   
Yesterday's Closing Price: $12.92 Daily Weekly Monthly
20 Day Moving Average: 75,534 shares
Shares Outstanding: 40.50 (millions)
Market Capitalization: $523.30 (millions)
Beta: 0.61
52 Week High: $20.54
52 Week Low: $11.75
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -9.71% -13.13%
12 Week -17.66% -23.56%
Year To Date -3.65% -12.36%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
GLENPOINTE CENTRE EAST 3RD FLOOR 300 FRANK W. BURR BLVD. SUITE 21
-
TEANECK,NJ 07666
USA
ph: 201-329-7300
fax: 201-329-7399
investor.relations@pahc.com http://www.pahc.com
 
 • General Corporate Information   
Officers
Jack C. Bendheim - Chairman; President and Chief Executive Officer
Damian Finio - Chief Financial Officer
Daniel M. Bendheim - Director and Executive Vice President
Jonathan Bendheim - Director and President
Gerald K. Carlson - Director

Peer Information
Phibro Animal Health Corporation (BJCT)
Phibro Animal Health Corporation (CADMQ)
Phibro Animal Health Corporation (APNO)
Phibro Animal Health Corporation (UPDC)
Phibro Animal Health Corporation (IMTIQ)
Phibro Animal Health Corporation (CYGN)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED PRODUCTS
Sector: Medical
CUSIP: 71742Q106
SIC: 2834
Fiscal Year
Fiscal Year End: June
Last Reported Quarter: 03/01/23
Next Expected EPS Date: 08/23/23
Share - Related Items
Shares Outstanding: 40.50
Most Recent Split Date: (:1)
Beta: 0.61
Market Capitalization: $523.30 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 3.72%
Current Fiscal Quarter EPS Consensus Estimate: $0.40 Indicated Annual Dividend: $0.48
Current Fiscal Year EPS Consensus Estimate: $1.24 Payout Ratio: 0.40
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: 0.04
Estmated Long-Term EPS Growth Rate: 1.50% Last Dividend Paid: 02/28/2023 - $0.12
Next EPS Report Date: 08/23/23  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 10.46
Trailing 12 Months: 10.77
PEG Ratio: 6.97
Price Ratios
Price/Book: 1.92
Price/Cash Flow: 6.05
Price / Sales: 0.54
EPS Growth
vs. Year Ago Period: -12.12%
vs. Previous Quarter: -14.71%
Sales Growth
vs. Year Ago Period: 2.55%
vs. Previous Quarter: 0.45%
ROE
03/31/23 - 18.13
12/31/22 - 18.90
09/30/22 - 19.90
ROA
03/31/23 - 5.07
12/31/22 - 5.33
09/30/22 - 5.63
Current Ratio
03/31/23 - 3.54
12/31/22 - 3.47
09/30/22 - 3.30
Quick Ratio
03/31/23 - 1.77
12/31/22 - 1.75
09/30/22 - 1.68
Operating Margin
03/31/23 - 4.94
12/31/22 - 5.15
09/30/22 - 5.34
Net Margin
03/31/23 - 2.92
12/31/22 - 3.73
09/30/22 - 4.85
Pre-Tax Margin
03/31/23 - 4.60
12/31/22 - 5.84
09/30/22 - 7.10
Book Value
03/31/23 - 6.72
12/31/22 - 6.63
09/30/22 - 6.49
Inventory Turnover
03/31/23 - 2.42
12/31/22 - 2.51
09/30/22 - 2.63
Debt-to-Equity
03/31/23 - 1.71
12/31/22 - 1.72
09/30/22 - 1.72
Debt-to-Capital
03/31/23 - 63.12
12/31/22 - 63.19
09/30/22 - 63.22
 

Powered by Zacks Investment Research ©